FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912112504> ?p ?o ?g. }

• W2912112504 endingPage "e024705" @default.
• W2912112504 startingPage "e024705" @default.
• W2912112504 abstract "Introduction Graves’ disease (Graves’ hyperthyroidism) is a challenging condition for the young person and their family. The excess thyroid hormone generated by autoimmune stimulation of the thyroid stimulating hormone receptor on the thyroid gland can have a profound impact on well-being. Managing the young person with Graves’ hyperthyroidism is more difficult than in older people because the side effects of conventional treatment are more significant in this age group and because the disease tends not to resolve spontaneously in the short to medium term. New immunomodulatory agents are available and the anti-B cell monoclonal antibody rituximab is of particular interest because it targets cells that manufacture the antibodies that stimulate the thyroid gland in Graves’. Methods and analysis The trial aims to establish whether the combination of a single dose of rituximab (500 mg) and a 12-month course of antithyroid drug (usually carbimazole) can result in a meaningful increase in the proportion of patients in remission at 2 years, the primary endpoint. A single-stage, phase II A’Hern design is used. 27 patients aged 12–20 years with newly presenting Graves’ hyperthyroidism will be recruited. Markers of immune function, including lymphocyte numbers and antibody levels (total and specific), will be collected regularly throughout the trial. Discussion The trial will determine whether the immunomodulatory medication, rituximab, will facilitate remission above and beyond that observed with antithyroid drug alone. A meaningful increase in the expected proportion of young patients entering remission when managed according to the trial protocol will justify consideration of a phase III trial. Ethics and dissemination The trial has received a favourable ethical opinion (North East - Tyne and Wear South Research Ethics Committee, reference 16/NE/0253, EudraCT number 2016-000209-35). The results of this trial will be distributed at international endocrine meetings, in the peer-reviewed literature and via patient support groups. Trial registration number ISRCTN20381716 ." @default.
• W2912112504 created "2019-02-21" @default.
• W2912112504 creator A5004246055 @default.
• W2912112504 creator A5010422931 @default.
• W2912112504 creator A5014775194 @default.
• W2912112504 creator A5015317444 @default.
• W2912112504 creator A5026203609 @default.
• W2912112504 creator A5029243250 @default.
• W2912112504 creator A5032397036 @default.
• W2912112504 creator A5032716539 @default.
• W2912112504 creator A5046495186 @default.
• W2912112504 creator A5074650917 @default.
• W2912112504 creator A5081480254 @default.
• W2912112504 creator A5084476692 @default.
• W2912112504 creator A5090229750 @default.
• W2912112504 creator A5090484443 @default.
• W2912112504 date "2019-01-01" @default.
• W2912112504 modified "2023-09-23" @default.
• W2912112504 title "Adjuvant rituximab, a potential treatment for the young patient with Graves’ hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial" @default.
• W2912112504 cites W1507812214 @default.
• W2912112504 cites W1888479777 @default.
• W2912112504 cites W1992904825 @default.
• W2912112504 cites W1998618256 @default.
• W2912112504 cites W2005305700 @default.
• W2912112504 cites W2024399892 @default.
• W2912112504 cites W2026800023 @default.
• W2912112504 cites W2038398254 @default.
• W2912112504 cites W2041007268 @default.
• W2912112504 cites W2042172469 @default.
• W2912112504 cites W2045069447 @default.
• W2912112504 cites W2049558499 @default.
• W2912112504 cites W2080637533 @default.
• W2912112504 cites W2094135291 @default.
• W2912112504 cites W2099402970 @default.
• W2912112504 cites W2103357079 @default.
• W2912112504 cites W2107348591 @default.
• W2912112504 cites W2107642899 @default.
• W2912112504 cites W2110391738 @default.
• W2912112504 cites W2115135526 @default.
• W2912112504 cites W2118994799 @default.
• W2912112504 cites W2120113475 @default.
• W2912112504 cites W2134617075 @default.
• W2912112504 cites W2135856630 @default.
• W2912112504 cites W2141111992 @default.
• W2912112504 cites W2147374444 @default.
• W2912112504 cites W2157437551 @default.
• W2912112504 cites W2158064334 @default.
• W2912112504 cites W2158151073 @default.
• W2912112504 cites W2167716419 @default.
• W2912112504 cites W2191505044 @default.
• W2912112504 cites W2337157164 @default.
• W2912112504 cites W2533874699 @default.
• W2912112504 cites W2552709271 @default.
• W2912112504 cites W2731755024 @default.
• W2912112504 cites W2769275072 @default.
• W2912112504 cites W2786469442 @default.
• W2912112504 cites W4210957724 @default.
• W2912112504 cites W4239857004 @default.
• W2912112504 cites W4242960669 @default.
• W2912112504 cites W4243016805 @default.
• W2912112504 doi "https://doi.org/10.1136/bmjopen-2018-024705" @default.
• W2912112504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6347892" @default.
• W2912112504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30670519" @default.
• W2912112504 hasPublicationYear "2019" @default.
• W2912112504 type Work @default.
• W2912112504 sameAs 2912112504 @default.
• W2912112504 citedByCount "6" @default.
• W2912112504 countsByYear W29121125042019 @default.
• W2912112504 countsByYear W29121125042021 @default.
• W2912112504 countsByYear W29121125042022 @default.
• W2912112504 crossrefType "journal-article" @default.
• W2912112504 hasAuthorship W2912112504A5004246055 @default.
• W2912112504 hasAuthorship W2912112504A5010422931 @default.
• W2912112504 hasAuthorship W2912112504A5014775194 @default.
• W2912112504 hasAuthorship W2912112504A5015317444 @default.
• W2912112504 hasAuthorship W2912112504A5026203609 @default.
• W2912112504 hasAuthorship W2912112504A5029243250 @default.
• W2912112504 hasAuthorship W2912112504A5032397036 @default.
• W2912112504 hasAuthorship W2912112504A5032716539 @default.
• W2912112504 hasAuthorship W2912112504A5046495186 @default.
• W2912112504 hasAuthorship W2912112504A5074650917 @default.
• W2912112504 hasAuthorship W2912112504A5081480254 @default.
• W2912112504 hasAuthorship W2912112504A5084476692 @default.
• W2912112504 hasAuthorship W2912112504A5090229750 @default.
• W2912112504 hasAuthorship W2912112504A5090484443 @default.
• W2912112504 hasBestOaLocation W29121125041 @default.
• W2912112504 hasConcept C126322002 @default.
• W2912112504 hasConcept C187212893 @default.
• W2912112504 hasConcept C203092338 @default.
• W2912112504 hasConcept C2776606491 @default.
• W2912112504 hasConcept C2776652619 @default.
• W2912112504 hasConcept C2777863537 @default.
• W2912112504 hasConcept C2779338263 @default.
• W2912112504 hasConcept C2779442721 @default.
• W2912112504 hasConcept C2780653079 @default.
• W2912112504 hasConcept C526584372 @default.
• W2912112504 hasConcept C535046627 @default.
• W2912112504 hasConcept C71924100 @default.

• next